Worse survival was associated with higher performance status, baseline WCCs, clinical secondary disease, +8, −5/del5q, −7/abn7q, −17/abn17p, MECOMr, del9q, and mutations in JAK2, KIT, or TP53. Multivariable regression including factors significant on univariable analysis and genomic abnormalities present in >3% of patients is shown in Figure 3C. Mutations in NPM1, RUNX1, STAG2, and IDH2 were associated with improved survival, whereas age, secondary and therapy-related AML, +8, inv3/t(3;3), complex karyotype, ASXL1, and KIT mutations were associated with poorer survival. This evidence concerns the gene RUNX1 and acute myeloid leukemia.